Intra-arterial administration of thrombolytic therapy (mainly tissue-plasminogen activator [t-PA]) has demonstrated significant and immediate clinical improvement, dubbed the "Lazarus phenomenon," in about one-fourth of patients with acute ischemic stroke. Factors associated with the Lazarus phenomenon are a shorter time to treatment, a high reperfusion score, and formation of good pial collaterals.
Intra-arterial administration of thrombolytic therapy (mainly tissue-plasminogen activator [t-PA]) has demonstrated significant and immediate clinical improvement, dubbed the "Lazarus phenomenon," in about one-fourth of patients with acute ischemic stroke. Factors associated with the Lazarus phenomenon are a shorter time to treatment, a high reperfusion score, and formation of good pial collaterals.
Intra-arterial delivery of t-PA directly into a clot, which has not been approved by FDA, was studied in 108 consecutive acute stroke patients presenting within 6 hours of symptom onset (patients with basilar artery thrombosis were treated within 24 hours of symptom onset). For this study, the Lazarus phenomenon was defined as a decrease in the National Institutes of Health (NIH) Stroke Scale score of ≥50% within 24 hours of treatment.
Arteriograms were reviewed to assess reperfusion on the basis of thrombolysis in cerebral infarction (TICI) score and to assess pial collateral formation. A TICI score of 0 designated no reperfusion to the affected region; a maximum score of 3 designated complete reperfusion to the affected territory. A score of 1 designated reperfusion <50%, and a score of 2 designated reperfusion of >50% to the affected territory but without complete recanalization.
Patients who experienced the Lazarus phenomenon were treated a mean of 198 minutes from symptom onset, compared with 299 minutes for those who did not experience significant and immediate improvement (P=.0002).
Another significant factor was pial collateral formation: 92.3% of those who experienced the Lazarus phenomenon had good pial collaterals, compared with 59.7% of those who did not experience the Lazarus phenomenon (P=.0022).
"Patients with brisk collaterals and who get in quickly have a much better chance at a dramatic outcome," Dr Christoforidis said. Approximately 50% of the patients with good pial collaterals who were treated in <270 minutes experienced the Lazarus phenomenon. In contrast, none of the patients with poor collaterals who were treated >270 minutes after symptom onset had this type of improvement.
TICI reperfusion score was also related to outcome. Half of the patients with TICI 2 or 3 reperfusion who were treated in <270 minutes experienced the Lazarus phenomenon; about one-fourth of patients with TICI 2 or 3 reperfusion who were treated >270 minutes also had rapid and significant improvement; of the patients with TICI 0 or 1 reperfusion, <10% experienced the Lazarus phenomenon.
Patients who experienced the Lazarus phenomenon improved by a median of 10 points on the NIH Stroke Scale in the first 24 hours, and improved by 0 points between the first 24 hours and hospital discharge. The majority of significant clinical improvement occurred within the first 24 hours, Dr Christoforidis said.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More